Cargando…
Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
BACKGROUND: Although the validity and safety of antipsychotic polypharmacy remains unclear, it is commonplace in the treatment of schizophrenia. This study aimed to investigate the degree that antipsychotic polypharmacy contributed to metabolic syndrome in outpatients with schizophrenia, after adjus...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155482/ https://www.ncbi.nlm.nih.gov/pubmed/21791046 http://dx.doi.org/10.1186/1471-244X-11-118 |
_version_ | 1782210122269851648 |
---|---|
author | Misawa, Fuminari Shimizu, Keiko Fujii, Yasuo Miyata, Ryouji Koshiishi, Fumio Kobayashi, Mihoko Shida, Hirokazu Oguchi, Yoshiyo Okumura, Yasuyuki Ito, Hiroto Kayama, Mami Kashima, Haruo |
author_facet | Misawa, Fuminari Shimizu, Keiko Fujii, Yasuo Miyata, Ryouji Koshiishi, Fumio Kobayashi, Mihoko Shida, Hirokazu Oguchi, Yoshiyo Okumura, Yasuyuki Ito, Hiroto Kayama, Mami Kashima, Haruo |
author_sort | Misawa, Fuminari |
collection | PubMed |
description | BACKGROUND: Although the validity and safety of antipsychotic polypharmacy remains unclear, it is commonplace in the treatment of schizophrenia. This study aimed to investigate the degree that antipsychotic polypharmacy contributed to metabolic syndrome in outpatients with schizophrenia, after adjustment for the effects of lifestyle. METHODS: A cross-sectional survey was carried out between April 2007 and October 2007 at Yamanashi Prefectural KITA hospital in Japan. 334 patients consented to this cross-sectional study. We measured the components consisting metabolic syndrome, and interviewed the participants about their lifestyle. We classified metabolic syndrome into four groups according to the severity of metabolic disturbance: the metabolic syndrome; the pre-metabolic syndrome; the visceral fat obesity; and the normal group. We used multinomial logistic regression models to assess the association of metabolic syndrome with antipsychotic polypharmacy, adjusting for lifestyle. RESULTS: Seventy-four (22.2%) patients were in the metabolic syndrome group, 61 (18.3%) patients were in the pre-metabolic syndrome group, and 41 (12.3%) patients were in visceral fat obesity group. Antipsychotic polypharmacy was present in 167 (50.0%) patients. In multinomial logistic regression analyses, antipsychotic polypharmacy was significantly associated with the pre-metabolic syndrome group (adjusted odds ratio [AOR], 2.348; 95% confidence interval [CI], 1.181-4.668), but not with the metabolic syndrome group (AOR, 1.269; 95%CI, 0.679-2.371). CONCLUSIONS: These results suggest that antipsychotic polypharmacy, compared with monotherapy, may be independently associated with an increased risk of having pre-metabolic syndrome, even after adjusting for patients' lifestyle characteristics. As metabolic syndrome is associated with an increased risk of cardiovascular mortality, further studies are needed to clarify the validity and safety of antipsychotic polypharmacy. |
format | Online Article Text |
id | pubmed-3155482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31554822011-08-13 Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study Misawa, Fuminari Shimizu, Keiko Fujii, Yasuo Miyata, Ryouji Koshiishi, Fumio Kobayashi, Mihoko Shida, Hirokazu Oguchi, Yoshiyo Okumura, Yasuyuki Ito, Hiroto Kayama, Mami Kashima, Haruo BMC Psychiatry Research Article BACKGROUND: Although the validity and safety of antipsychotic polypharmacy remains unclear, it is commonplace in the treatment of schizophrenia. This study aimed to investigate the degree that antipsychotic polypharmacy contributed to metabolic syndrome in outpatients with schizophrenia, after adjustment for the effects of lifestyle. METHODS: A cross-sectional survey was carried out between April 2007 and October 2007 at Yamanashi Prefectural KITA hospital in Japan. 334 patients consented to this cross-sectional study. We measured the components consisting metabolic syndrome, and interviewed the participants about their lifestyle. We classified metabolic syndrome into four groups according to the severity of metabolic disturbance: the metabolic syndrome; the pre-metabolic syndrome; the visceral fat obesity; and the normal group. We used multinomial logistic regression models to assess the association of metabolic syndrome with antipsychotic polypharmacy, adjusting for lifestyle. RESULTS: Seventy-four (22.2%) patients were in the metabolic syndrome group, 61 (18.3%) patients were in the pre-metabolic syndrome group, and 41 (12.3%) patients were in visceral fat obesity group. Antipsychotic polypharmacy was present in 167 (50.0%) patients. In multinomial logistic regression analyses, antipsychotic polypharmacy was significantly associated with the pre-metabolic syndrome group (adjusted odds ratio [AOR], 2.348; 95% confidence interval [CI], 1.181-4.668), but not with the metabolic syndrome group (AOR, 1.269; 95%CI, 0.679-2.371). CONCLUSIONS: These results suggest that antipsychotic polypharmacy, compared with monotherapy, may be independently associated with an increased risk of having pre-metabolic syndrome, even after adjusting for patients' lifestyle characteristics. As metabolic syndrome is associated with an increased risk of cardiovascular mortality, further studies are needed to clarify the validity and safety of antipsychotic polypharmacy. BioMed Central 2011-07-26 /pmc/articles/PMC3155482/ /pubmed/21791046 http://dx.doi.org/10.1186/1471-244X-11-118 Text en Copyright ©2011 Misawa et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Misawa, Fuminari Shimizu, Keiko Fujii, Yasuo Miyata, Ryouji Koshiishi, Fumio Kobayashi, Mihoko Shida, Hirokazu Oguchi, Yoshiyo Okumura, Yasuyuki Ito, Hiroto Kayama, Mami Kashima, Haruo Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study |
title | Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study |
title_full | Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study |
title_fullStr | Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study |
title_full_unstemmed | Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study |
title_short | Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study |
title_sort | is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155482/ https://www.ncbi.nlm.nih.gov/pubmed/21791046 http://dx.doi.org/10.1186/1471-244X-11-118 |
work_keys_str_mv | AT misawafuminari isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy AT shimizukeiko isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy AT fujiiyasuo isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy AT miyataryouji isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy AT koshiishifumio isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy AT kobayashimihoko isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy AT shidahirokazu isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy AT oguchiyoshiyo isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy AT okumurayasuyuki isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy AT itohiroto isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy AT kayamamami isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy AT kashimaharuo isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy |